| Company | Exchange
| Symbol
| Last price
|
| Quote change
| Market cap
|
|
|
GlaxoSmithKline plc
| LON
|
GSK
|
1,742.00
|
|
-31.00
(-1.75%)
| 84,382.48M
|
|
|
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the
creation and discovery, development, manufacture and marketing of ...
| |
| |
|
|
GlaxoSmithKline plc (ADR)
| NYSE
|
GSK
|
52.64
|
|
-0.30
(-0.57%)
| 129,220.55M
|
|
|
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the
creation and discovery, development, manufacture and marketing of ...
| |
| |
|
|
IPG Investment Partners Group AG
| ETR
|
GSK
|
0.0000
|
|
|
|
|
|
IPG Investment Partners Group AG, formerly known as IPG Investment Partners
Group Wertpapierhandelsbank AG, is a Germany-based investment bank for ...
| |
| |
|
|
GlaxoSmithKline PLC
| FRA
|
GS7
|
20.31
|
|
-0.36
(-1.76%)
|
|
|
|
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the
creation and discovery, development, manufacture and marketing of ...
| |
| |
|
|
Cyclacel Pharmaceuticals Inc
| NASDAQ
|
CYCC
|
3.11
|
|
+0.12
(4.01%)
| 26.23M
|
|
|
Cyclacel Pharmaceuticals, Inc. develops therapies that harness the power of the
immune system to treat cancer and other serious illnesses.
| |
| |
|
|
Cytokinetics, Inc.
| NASDAQ
|
CYTK
|
1.11
|
|
-0.02
(-1.77%)
| 162.57M
|
|
|
Cytokinetics, Incorporated (Cytokinetics) is a biopharmaceutical company focused
on the discovery and development of small molecule therapeutics that ...
| |
| |
|
|
Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock
| NASDAQ
|
CYCCP
|
7.66
|
|
0.00
(0.00%)
| 3.22M
|
|
|
|
|
|
CYCLACEL PHARM. DL-,001
| FRA
|
UXI2
|
2.36
|
|
+0.04
(1.68%)
|
|
|
|
|
|
|
CYTOKINETICS INC. DL-,001
| FRA
|
KK3
|
0.874
|
|
-0.010
(-1.13%)
|
|
|
|
|
|
